[EN] SILYLATED PYRIMIDINE PRODRUGS AND METHODS OF THEIR USE [FR] PROMÉDICAMENTS SOUS FORME DE PYRIMIDINE SILYLÉE ET MÉTHODES D'UTILISATION DESDITS PROMÉDICAMENTS
FLUORINATED PYRIMIDINE ANALOGS AND METHODS OF USE THEREOF
申请人:Daifuku Richard
公开号:US20140024612A1
公开(公告)日:2014-01-23
Fluorinated pyrimidine analog compounds, compositions that include the fluorinated pyrimidine analog compounds, methods for making the fluorinated pyrimidine analog compounds, and methods for inhibiting DNA methyltransferase, treating solid tumors, and treating hematologic cancers by administering the fluorinated pyrimidine analog compounds.
Compounds and compositions of azacytosine analogs and derivatives are provided. In one aspect of the invention, analogs or derivatives of decitabine and azacitidine are provided with modification at the 4- and 6-position of the triazine ring, at the 1′-6′position of the ribose ring, or combinations thereof. Methods of synthesizing and manufacturing these analogs and derivatives are also provided. These compounds can be formulated into pharmaceutical compositions that can be used for treating any disease that is sensitive to the treatment with decitabine or azacitidine, such as hematological disorders and cancer.
[EN] METHOD OF TREATMENT OF TP53 WILD-TYPE TUMORS WITH 2',2'-DIFLUORO-5-AZA-2'-DEOXYCYTIDINE OR PRODRUGS THEREOF<br/>[FR] MÉTHODE DE TRAITEMENT DE TUMEURS TP53 DE TYPE SAUVAGE À L'AIDE DE 2',2'-DIFLUORO-5-AZA-2'-DÉSOXYCYTIDINE OU DE PROMÉDICAMENTS DE CELLE-CI
申请人:EPIGENETICS PHARMA LLC
公开号:WO2017143453A1
公开(公告)日:2017-08-31
This disclosure provides methods and strategies for inhibiting the growth of TP53 wild-type cancer cells, comprising contacting the cell with 2',2'-difluoro-5-aza-2'- deoxycytidine or a 2',2'-difluoro-5-aza-2'-deoxycytidine prodrug. Also provided are related methods for treating a cancer characterized by having wild-type TP53 in a subject in need thereof.
[EN] COMBINATION THERAPY FOR TREATING MALIGNANCIES<br/>[FR] POLYTHÉRAPIE POUR LE TRAITEMENT DE MALIGNITÉS
申请人:CELGENE CORP
公开号:WO2017066611A1
公开(公告)日:2017-04-20
Provided are methods and compositions for treating cancers in patients carrying an IDH2 mutation using a combination of an inhibitor of a mutant IDH2 enzyme and a DNA demethylating agent.